Stockreport

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-a4ß7 Antibody, for the Treatment of Inflammatory Bowel Disease [Yahoo! F...

Spyre Therapeutics, Inc.  (SYRE) 
PDF Interim subcutaneous pharmacokinetic and safety data from healthy volunteers anticipated by year-end 2024 SPY002, an extended half-life anti-TL1A antibody designed fo [Read more]